Sage Journals: Discover world-class research

Abstract

Background

Hypertension complicated with left ventricular hypertrophy (LVH) and diastolic dysfunction is one of the most common risks for heart failure with preserved ejection fraction (HFpEF). This study was designed to evaluate the influences of long-term beta-blocker prescription in these patients.

Methods

This retrospective analysis included eligible patients diagnosed with hypertension, LVH (left ventricular (LV) mass index >125 g/m² for men and >110 g/m² for women) and suspected diastolic dysfunction (E/E’ ratio between 8 and 15) and without clinical signs or symptoms of heart failure in our hospital medical record database (January 2005–December 2009). A total of eligible 1498 patients were enrolled, of whom 803 received beta-blocker prescription and 695 accepted non-beta-blocker therapy.

Results

With a median follow-up of 7.2 years, the new-onset symptomatic HFpEF occurred in 48 of 803 patients in the beta-blocker group (6.0%) and 92 of 695 patients in the non-beta-blocker group (13.2%, p < 0.001). Beta-blockers also generated more prominent improvement in diastolic function and LVH. And Cox proportional hazards model revealed that beta-blocker (hazard ratio (HR) 0.327, 95% confidence interval (CI): 0.121–0.540, p = 0.009) or angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker (ACEI/ARB) exposure (HR 0.422, 95% CI: 0.210–0.699, p = 0.015) was associated with a reduced risk of new onset of symptomatic HFpEF, and the elevation of LVMI (HR 1.210, 95% CI: 1.069–1.362, p = 0.040) or E/E’ (HR 1.398, 95% CI: 1.306–1.541, p = 0.032) was associated with a high risk of new onset of symptomatic HFpEF.

Conclusions

Long-term beta-blocker exposure was associated with protective effects in terms of the incidence of new-onset symptomatic HFpEF, LV diastolic dysfunction and LVH, which might be beneficial for the delay of HFpEF progression.

Keywords

Beta-blocker heart failure with preserved ejection fraction hypertension left ventricular hypertrophy diastolic dysfunction

Get full access to this article

View all access options for this article.

References

Yancy

Jessup

Bozkurt

. American College of Cardiology Foundation; American Heart Association Task Force on Practice Guidelines. 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2013; 62: e147–e239.

Tannenbaum

Sayer

. Advances in the pathophysiology and treatment of heart failure with preserved ejection fraction. Curr Opin Cardiol 2015; 30: 250–258.

Nadruz

. Myocardial remodeling in hypertension. J Hum Hypertens 2015; 29: 1–6.

Melenovsky

Borlaug

Rosen

. Cardiovascular features of heart failure with preserved ejection fraction versus nonfailing hypertensive left ventricular hypertrophy in the urban Baltimore community: The role of atrial remodeling/dysfunction. J Am Coll Cardiol 2007; 49: 198–207.

Chen

Jiang

Wang

. Predictive value of plasma galectin-3 in patients with chronic heart failure. Eur Rev Med Pharmacol Sci 2013; 17: 1005–1011.

Franco

Formiga

Chivite

. RICA investigators. New onset heart failure–clinical characteristics and short-term mortality. A RICA (Spanish registry of acute heart failure) study. Eur J Intern Med 2015; 26: 357–362.

Campbell

Sorrell

. Cell and molecular level mechanisms contributing to diastolic dysfunction in HFpEF. J Appl Physiol (1985) 2015; 119: 1228–1232.

Upadhya

Taffet

Cheng

. Heart failure with preserved ejection fraction in the elderly: Scope of the problem. J Mol Cell Cardiol 2015; 83: 73–87.

Palazzuoli

Bruni

Puccetti

. Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failure. Eur J Heart Fail 2002; 4: 765–770.

10.

Magrì

Agostoni

Corrà

. Metabolic Exercise test data combined with Cardiac and Kidney Indexes (MECKI) Score Research Group. Deceptive meaning of oxygen uptake measured at the anaerobic threshold in patients with systolic heart failure and atrial fibrillation. Eur J Prev Cardiol 2015; 22: 1046–1055.

11.

El-Refai

Peterson

Wells

. Comparison of β-blocker effectiveness in heart failure patients with preserved ejection fraction versus those with reduced ejection fraction. J Card Fail 2013; 19: 73–79.

12.

Hernandez

Hammill

O’Connor

. Clinical effectiveness of beta-blockers in heart failure: Findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) Registry. J Am Coll Cardiol 2009; 53: 184–192.

13.

Patel

Fonarow

Ekundayo

. Beta-blockers in older patients with heart failure and preserved ejection fraction: Class, dosage, and outcomes. Int J Cardiol 2014; 173: 393–401.

14.

Yamamoto

Origasa

Hori

. J-DHF investigators. Effects of carvedilol on heart failure with preserved ejection fraction: The Japanese Diastolic Heart Failure Study (J-DHF). Eur J Heart Fail 2013; 15: 110–118.

15.

Conraads

Metra

Kamp

. Effects of the long-term administration of nebivolol on the clinical symptoms, exercise capacity, and left ventricular function of patients with diastolic dysfunction: Results of the ELANDD study. Eur J Heart Fail 2012; 14: 219–225.

16.

Yamamoto

. β-Blocker therapy in heart failure with preserved ejection fraction: Importance of dose and duration. J Cardiol 2015; 66: 189–194.

17.

Grandi

Solbiati

Laurita

. Effects of dual blockade of renin-angiotensin system on concentric left ventricular hypertrophy in essential hypertension: A randomized, controlled pilot study. Am J Hypertens 2008; 21: 231–237.

18.

Motoki

Koyama

Izawa

. Impact of azelnidipine and amlodipine on left ventricular mass and longitudinal function in hypertensive patients with left ventricular hypertrophy. Echocardiography 2014; 31: 1230–1238.

19.

Yamamoto

Ozaki

Takayasu

. The effect of losartan and amlodipine on left ventricular diastolic function and atherosclerosis in Japanese patients with mild-to-moderate hypertension (J-ELAN) study. Hypertens Res 2011; 34: 325–330.

20.

Takahashi

Minatoguchi

Nishigaki

. Long-term and strict blood pressure lowering by imidapril reverses left ventricular hypertrophy in patients with essential hypertension: An evaluation using a novel indicator of burden on the left ventricle. Hypertens Res 2006; 29: 89–94.

21.

Westendorp

Schoemaker

Buikema

. Progressive left ventricular hypertrophy after withdrawal of long-term ACE inhibition following experimental myocardial infarction. Eur J Heart Fail 2006; 8: 122–130.

22.

Susic

Fares

Frohlich

. Nebivolol prevents myocardial fibrosis and diastolic dysfunction in salt-loaded spontaneously hypertensive rats. J Am Soc Hypertens 2012; 6: 316–323.

23.

Kawaguchi

Hay

Fetics

. Combined ventricular systolic and arterial stiffening in patients with heart failure and preserved ejection fraction: Implications for systolic and diastolic reserve limitations. Circulation 2003; 107: 714–720.

24.

Lechat

Hulot

Escolano

. Heart rate and cardiac rhythm relationships with bisoprolol benefit in chronic heart failure in CIBIS II Trial. Circulation 2001; 103: 1428–1433.

25.

Nishio

Sakata

Mano

. Beneficial effects of bisoprolol on the survival of hypertensive diastolic heart failure model rats. Eur J Heart Fail 2008; 10: 446–453.

26.

Ichihara

Yamada

Ichihara

. Attenuation of oxidative stress and cardiac dysfunction by bisoprolol in an animal model of dilated cardiomyopathy. Biochem Biophys Res Commun 2006; 350: 105–113.

27.

Pascotto

Leong-Poi

. Anti-inflammatory and pro-angiogenic effects of beta blockers in a canine model of chronic ischemic cardiomyopathy: Comparison between carvedilol and metoprolol. Basic Res Cardiol 2013; 108: 384–384.

28.

Gul

Habibi

. Nebivolol improves diastolic dysfunction and myocardial remodeling through reductions in oxidative stress in the transgenic (mRen2) rat. Am J Physiol Heart Circ Physiol 2012; 302: H2341–H2351.

29.

Kelly

Gonzalez-Campoy

Rudser

. Carvedilol-lisinopril combination therapy and endothelial function in obese individuals with hypertension. J Clin Hypertens (Greenwich) 2012; 14: 85–91.

30.

Weber

Basile

Stapff

. Blood pressure effects of combined β-blocker and angiotensin-converting enzyme inhibitor therapy compared with the individual agents: A placebo-controlled study with nebivolol and lisinopril. J Clin Hypertens (Greenwich) 2012; 14: 588–592.

31.

Saul

Duprez

Zhong

. Effect of carvedilol, lisinopril and their combination on vascular and cardiac health in patients with borderline blood pressure: The DETECT study. J Hum Hypertens 2013; 27: 362–367.

32.

Maruyama

Masaki

Sato

. Effect of angiotensin converting enzyme inhibitors and beta-blockers on left ventricular remodeling after coronary artery bypass graft surgery. Int Heart J 2008; 49: 385–390.

33.

Degirmenci

Açikel

Bakirci

. Comparison of effects of nebivolol, carvedilol and irbesartan on left ventricular hypertrophy associated with hypertension. Eur Rev Med Pharmacol Sci 2014; 18: 630–637.

34.

Signorovitch

Samuelson

Ramakrishnan

. Persistence with nebivolol in the treatment of hypertension: A retrospective claims analysis. Curr Med Res Opin 2012; 28: 591–599.

Long-term prescription of beta-blocker delays the progression of heart failure with preserved ejection fraction in patients with hypertension: A retrospective observational cohort study

Abstract

Background

Methods

Results

Conclusions

Keywords

Get full access to this article

References